Modeling inducible neuropathologies of the retina with differential phenotypes in organoids

Front Cell Neurosci. 2023 May 5:17:1106287. doi: 10.3389/fncel.2023.1106287. eCollection 2023.

Abstract

Neurodegenerative diseases remain incompletely understood and therapies are needed. Stem cell-derived organoid models facilitate fundamental and translational medicine research. However, to which extent differential neuronal and glial pathologic processes can be reproduced in current systems is still unclear. Here, we tested 16 different chemical, physical, and cell functional manipulations in mouse retina organoids to further explore this. Some of the treatments induce differential phenotypes, indicating that organoids are competent to reproduce distinct pathologic processes. Notably, mouse retina organoids even reproduce a complex pathology phenotype with combined photoreceptor neurodegeneration and glial pathologies upon combined (not single) application of HBEGF and TNF, two factors previously associated with neurodegenerative diseases. Pharmacological inhibitors for MAPK signaling completely prevent photoreceptor and glial pathologies, while inhibitors for Rho/ROCK, NFkB, and CDK4 differentially affect them. In conclusion, mouse retina organoids facilitate reproduction of distinct and complex pathologies, mechanistic access, insights for further organoid optimization, and modeling of differential phenotypes for future applications in fundamental and translational medicine research.

Keywords: glia; mouse embryonic stem (mES) cells; mouse organoid; neurodegeneration; neuron; pathology modeling; photoreceptor; retina.

Grants and funding

This work was supported by the Funding Programs for DZNE Helmholtz (MK), TU Dresden CRTD (MK), DFG KA2794/3-1 SPP1738 (MK), HGF ExNet-007 (MK), DFG KA2794/5-1 and KA2794/5-2 SPP2127 (MK), ERA-NET NEURON and BMBF 01EW2106, ReDiMoAMD (MK), BMBF PACETherapy, 01EJ2206A (MK), EyeNovative Award (Novartis Pharma GmbH) (MK), TU Dresden CRTD Seed Grant (MK), and EFRE (EM-Facility, TK). The Article Processing Charges (APC) were funded by the joint publication fund of the TU Dresden, the Medical Faculty Carl Gustav Carus, and the SLUB Dresden. MK received funding from Novartis Pharma GmbH for this study in the form of a research award, the EyeNovative Award, based on a research project proposal. Novartis Pharma GmbH was not involved in the study, i.e., had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.